Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conatumumab + mFOLFOX6
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**Conatumumab + mFOLFOX6** is a combination therapy of conatumumab, an investigational fully human monoclonal IgG1 antibody that specifically agonizes death receptor 5 (DR5), with the modified FOLFOX6 chemotherapy regimen. mFOLFOX6 consists of oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU). This combination was investigated for the first-line treatment of metastatic colorectal cancer (mCRC) in clinical trials, but addition of conatumumab did not improve efficacy over mFOLFOX6 with placebo. Conatumumab induces apoptosis of tumor cells via DR5 activation. mFOLFOX6 acts through DNA crosslinking (oxaliplatin), inhibition of thymidylate synthase (fluorouracil), and enhancement of 5-FU cytotoxicity (leucovorin)[1][2][3][6].
02
Targets
DNATS (Thymidylate synthase)TNFRSF10B (DR5)
Beyond the preview
Go deeper on conatumumab + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conatumumab + mFOLFOX6.